Amryt Pharma (AMYT)
Amryt Pharma is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.
Belvoir Group (BLV)
Founded in 1995 and listed on AIM in 2012, Belvoir Group is the UK’s largest property franchise operating nationwide from 396 offices across five brands specialising in residential lettings, property management, residential sales and property-related financial services. The Group manages 69,000 properties and reported record revenues of £19.3m in 2019.
Ncondezi Energy (NCCL)
A large thermal coal resource, strategically located in the Tete Province of Mozambique, which is capable of supporting a long life, open pit mining and power plant operation.
Open Orphan (ORPH)
is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and is actively involved in the fight against COVID-19.
ReNeuron Group (RENE)
ReNeuron Group (RENE) is a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
VolitionRX is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, VolitionRX products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
VolitionRX research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.